Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer.

Date publication

août 2016

Journal

Gynecologic oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MARCHAL Frédéric

Tous les auteurs :
Gouy S, Ferron G, Glehen O, Bayar A, Marchal F, Pomel C, Quenet F, Bereder JM, Le Deley MC, Morice P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27246305

Résumé

Hyperthermic intraperitoneal chemotherapy (HIPEC) may improve the outcome of patients with initially unresectable ovarian cancer who are eligible for complete cytoreductive surgery (CCRS) after neoadjuvant chemotherapy. The main objective of this multicenter phase-I study was to identify the recommended dose of cisplatin for HIPEC at CCRS after neoadjuvant carboplatin and paclitaxel (CP).

Référence

Gynecol. Oncol.. 2016 Aug;142(2):237-42